TENS Unit To Decrease Pain After Laminaria Insertion

December 15, 2025 updated by: Queen's Medical Center

Randomized Controlled Trial: TENS Unit To Decrease Pain After Laminaria Insertion

The purpose of the study is to learn more about the transcutaneous nerve stimulation (TENS) unit, an over-the-counter option for pain relief that is not a medication. The investigators are hoping to find out if this device decreases pain during and after laminaria placement for patients undergoing both elective and medically indicated second-trimester termination of pregnancy.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

To compare the maximum pain scores reported during the interval between osmotic dilator placement and D&E procedure of patients receiving the standard of care plus sham placebo and those who use an adjunctive Transcutaneous electrical nerve stimulation (TENS) unit in addition to standard of care.

Secondary objectives include comparing pain scores at the time of laminaria insertion, assessing the number and duration of TENS sessions, additional analgesic use, satisfaction with pain management, and patient perception of the ease of use of the TENS unit.

Study Type

Interventional

Enrollment (Actual)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Hawaii
      • Honolulu, Hawaii, United States, 96813
        • 1380 Lusitana St. Ste 1004

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients undergoing laminaria insertion for D&E procedure
  • Age 18 years or older
  • Capability and willingness to send and receive SMS messages by phone and complete web-based surveys
  • Capability to read and understand directions for using a TENS unit
  • Capability to operate a TENS unit according to provided directions

Exclusion Criteria:

  • Inability to complete the informed consent in English
  • Exposure to adjunctive pharmacologic cervical preparation (misoprostol or mifepristone) within 48 hours of the D&E procedure
  • Contraindication to ibuprofen or bupivacaine
  • Contraindication to TENS, including cardiac pacemakers, epilepsy, bleeding disorders, cancer, and concurrent use near transdermal drug delivery systems
  • Previous participation in this trial
  • Prior use of TENS unit

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Participants in the placebo group will be given a TENS unit without a battery with similar to the intervention group but will be advised that they may or may not feel a sensation from the electrodes. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.
Active Comparator: TENS unit
All participants in this study will receive the standard of care, which includes oral ibuprofen and a paracervical block at the time of laminaria insertion. Those in the treatment group will receive an adjunctive TENS unit with specific instructions for use in the interval between laminaria insertion and dilation and evacuation the next day. TENS is a non-invasive, inexpensive, over-the-counter, nonpharmacologic option to relieve pain. All participants will be provided with 15 tabs of ibuprofen 200 mg for outpatient pain control after the procedure. Participants will be instructed to take 600-800 mg of ibuprofen with food every 6 hours as needed for pain during the time period after laminaria insertion and before dilation and evacuation surgery, which is generally less than 24 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum pain scores
Time Frame: Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
To compare the maximum pain scores reported during the interval between osmotic dilator placement and D&E procedure of patients receiving the standard of care plus placebo and those who use an adjunctive transcutaneous electrical nerve stimulation (TENS) unit in addition to standard of care. Participants will be asked to rank their pain on an 11-point numerical rating scale (0 to 10), with higher numbers indicating worse pain.
Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain at time of laminaria insertion
Time Frame: At time of laminaria insertion
Pain scores at the time of laminaria insertion. Participants will be asked to rank their pain on an 11-point numerical rating scale (0 to 10), with higher numbers indicating worse pain.
At time of laminaria insertion
Number of TENS sessions
Time Frame: Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
Number of TENS sessions
Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
Duration of each TENS sessions
Time Frame: Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
Duration of each TENS sessions
Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
Satisfaction with pain management
Time Frame: Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
Participants will be asked "Overall satisfaction with pain control since the procedure: (0-10 numeric rating scale)" on all five surveys. A score of 0 indicates "extremely unsatisfied." A score of 5 indicates "neutral." A score of 10 indicates "extremely satisfied."
Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
Ease of use
Time Frame: Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
Perception of the ease of use of the TENS unit. At the initial 10-minute mark survey, participants will be asked, "How difficult do you feel it will be to use a TENS unit? (0-10 numeric rating scale)". On the final survey (pre-op survey), only participants in the intervention group will be asked, "How difficult was it to use a TENS unit? (0-10 numeric rating scale)". A score of 0 indicates "not difficult at all." A score of 10 indicates "very difficult."
Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
Analgesic use
Time Frame: Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)
Amount of ibuprofen taken and/or other analgesics
Between osmotic dilator placement and dilation and evacuation procedure (approximately 16-24 hours)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Study Director: Melissa Natavio, MD, MPH, Complex Family Planning, The Queens Medical Center, Department of Obstetrics, Gynecology, and Womens Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 14, 2024

Primary Completion (Actual)

November 5, 2025

Study Completion (Actual)

November 5, 2025

Study Registration Dates

First Submitted

July 9, 2024

First Submitted That Met QC Criteria

July 29, 2024

First Posted (Actual)

July 31, 2024

Study Record Updates

Last Update Posted (Actual)

December 16, 2025

Last Update Submitted That Met QC Criteria

December 15, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • RA-2024-018

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.